Wikipedia

Monocarboxylate transporter 1

(Redirected from SLC16A1)

Monocarboxylate transporter 1 is a ubiquitous protein that in humans is encoded by the SLC16A1 gene (also known as MCT1).[5][6][7] It is a proton coupled monocarboxylate transporter.

SLC16A1
Identifiers
AliasesSLC16A1, HHF7, MCT, MCT1, MCT1D, solute carrier family 16 member 1
External IDsOMIM: 600682; MGI: 106013; HomoloGene: 20662; GeneCards: SLC16A1; OMA:SLC16A1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

6566

20501

Ensembl

ENSG00000155380
ENSG00000281917

ENSMUSG00000032902

UniProt

P53985
Q5T8R3

P53986

RefSeq (mRNA)

NM_001166496
NM_003051

NM_009196

RefSeq (protein)

NP_001159968
NP_003042

NP_033222

Location (UCSC)Chr 1: 112.91 – 112.96 MbChr 3: 104.55 – 104.57 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Biochemistry

edit

Detailed kinetic analysis of monocarboxylate transport in erythrocytes revealed that MCT1 operates through an ordered mechanism. MCT1 has a substrate binding site open to the extracellular matrix which binds a proton first followed by the lactate anion. The protein then undergoes a conformational change to a new 'closed conformation that exposes both the proton and lactate to the opposite surface of the membrane where they are released, lactate first and then the proton. For net transport of lactic acid, the rate-limiting step is the return of MCT1 without bound substrate to the open conformation. For this reason, exchange of one monocarboxylate inside the cell with another outside is considerably faster than net transport of a monocarboxylate across the membrane.[citation needed]

MCT1 can be upregulated by PPAR-α, Nrf2, and AMPK.[8]

Animal studies

edit

Overexpression of MCT1 has been shown to increase the efficacy of an anti-cancer drug currently undergoing clinical trials called 3-bromopyruvate in breast cancer cells.[9]

Clinical significance

edit

Most cases of alveolar soft part sarcoma show PAS( ), diastase-resistant (PAS-D ( )) intracytoplasmic crystals which contain CD147 and monocarboxylate transporter 1 (MCT1).[10] Overexpression of MCT1 in pancreatic beta cells leads to hyperinsulinism during exercise.[11]

Hyperinsulinemic hypoglycemia, familial, 7 (HHF7) is an autosomal dominant disease on the SLC16A1/MCT gene on chromosome 1p13.2. It causes hyperinsulinemic hypoglycemia, where hyperinsulinism is exercise-induced.[12]

Monocarboxylate transporter 1 deficiency (MCTD1) is an autosomal dominant and recessive disease on the SLC16A1/MCT1 gene on chromosome 1p13.2. It causes poor feeding and vomiting, intellectual disability, ketotic hypoglycemia, ketoacidosis, ketonuria, with episodes brought on by fasting or infection.[13]

Erythrocyte lactate transporter defect (formerly, myopathy due to lactate transport defect) is an autosomal dominant disease on the SLC16A1/MCT gene on chromosome 1p.13.2. It causes exercise-induced muscle cramping, stiffness, and fatigue (exercise intolerance); symptoms may also be induced by heat. Although symptoms present in the muscles, muscle biopsy and EMG are normal. Decreased erythrocyte (red blood cell) lactate clearance, decreased lactate clearance from muscle after exercise, and elevated serum creatine kinase.[14]

References

edit
  1. ^ a b c ENSG00000281917 GRCh38: Ensembl release 89: ENSG00000155380, ENSG00000281917 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000032902 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Garcia CK, Goldstein JL, Pathak RK, Anderson RG, Brown MS (Mar 1994). "Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: implications for the Cori cycle". Cell. 76 (5): 865–73. doi:10.1016/0092-8674(94)90361-1. PMID 8124722. S2CID 22137883.
  6. ^ Garcia CK, Li X, Luna J, Francke U (Sep 1994). "cDNA cloning of the human monocarboxylate transporter 1 and chromosomal localization of the SLC16A1 locus to 1p13.2-p12". Genomics. 23 (2): 500–3. doi:10.1006/geno.1994.1532. PMID 7835905.
  7. ^ "Entrez Gene: SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1)".
  8. ^ Felmlee MA, Jones RS, Morris ME (2020). "Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease". Pharmacological Reviews. 72 (2): 466–485. doi:10.1124/pr.119.018762. PMC 7062045. PMID 32144120.
  9. ^ Liu Z, Sun Y, Hong H, Zhao S, Zou X, Ma R, Jiang C, Wang Z, Li H, Liu H (2015-08-15). "3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells". American Journal of Cancer Research. 5 (9): 2673–85. doi:10.1158/1538-7445.AM2015-2673. PMC 4633897. PMID 26609475.
  10. ^ Ladanyi M, Antonescu CR, Drobnjak M, Baren A, Lui MY, Golde DW, Cordon-Cardo C (Apr 2002). "The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147". The American Journal of Pathology. 160 (4): 1215–21. doi:10.1016/S0002-9440(10)62548-5. PMC 1867200. PMID 11943706.
  11. ^ Pullen TJ, Sylow L, Sun G, Halestrap AP, Richter EA, Rutter GA (Jul 2012). "Overexpression of monocarboxylate transporter-1 (SLC16A1) in mouse pancreatic β-cells leads to relative hyperinsulinism during exercise". Diabetes. 61 (7): 1719–25. doi:10.2337/db11-1531. PMC 3379650. PMID 22522610.
  12. ^ "HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 7; HHF7". omim.org. Retrieved 2023-08-21.
  13. ^ "MONOCARBOXYLATE TRANSPORTER 1 DEFICIENCY; MCT1D". omim.org. Retrieved 2023-08-21.
  14. ^ "ERYTHROCYTE LACTATE TRANSPORTER DEFECT". omim.org. Retrieved 2023-08-21.

Further reading

edit


 

This membrane protein–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Monocarboxylate_transporter_1&oldid=1254525657"